stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) EV/FCF
As of 5 November 2026, Amylyx Pharmaceuticals, Inc. (AMLX) trades at a EV/FCF of −21.7×. Over the past ten years it has ranged from −31.8× (August 2026) to 88.6× (February 2024); the current reading is higher than 4% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2024 | −0.4× | — |
| FY2023 | 59.6× | — |
| FY2022 | −9.6× | — |
| FY2021 | −0.3× | — |
| FY2020 | −0.3× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Dec 2024 | −0.4× | — |
| Sep 2024 | 0.1× | (96.91%) |
| Jun 2024 | 3.0× | — |
| Mar 2024 | −12.2× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. | −21.7× |
| RGC Regencell Bioscience Holdings Limited compare | 0.9× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 7.5× |
| TRLV Trulieve Cannabis Corp. compare | 12.0× |
| PBH Prestige Consumer Healthcare Inc. compare | 19.2× |
| LQDA Liquidia Corporation compare | 25.6× |
| PRGO Perrigo Company plc compare | 28.6× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| SUPN Indivior Pharmaceuticals Inc. compare | 138× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement